Tolerability, Safety, and Pharmacokinetics of Ivermectin After Nasal Application in Healthy Adult Subjects.

ABSTRACT: Nasal epithelium is the site of infection for SARS-CoV2 viruses, with interactions of the viral spike protein with the ACE2 receptor of the host cell. Molecular docking studies have shown that ivermectin shields the spike protein and thereby prevents binding to ACE2. Nasal application of high doses of ivermectin could be the right therapeutic approach in the treatment and prevention of COVID-19. Tolerability, safety, and pharmacokinetics of ivermectin, administered nasally as 5% microsuspension (F004), were investigated in a randomized, double-blind, parallel-groups, placebo-controlled phase 1 study in 28 healthy adults. Bioavailability of a single dose of 14 mg ivermectin was determined with AUC_0-t ^T of 1701.1 ng/mL h (AUC_0-∞ of 2382.7 ng/mL h, calculated)

SUBMITTER: Wissel S 

PROVIDER: S-EPMC12710153 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature